What Исентресс Treats: Main Uses and Benefits

The medicine is commonly used to support the management of Human Immunodeficiency Virus type 1 (HIV-1) infection. The medicine is relevant in situations involving certain distressing symptoms and is used in conditions where symptomatic management is applied over time.

The medicine is commonly used to help address symptom clusters that may become intense, such as those related to systemic imbalance and the weakening of the immune system. This medicine may assist with reducing the viral load in the bloodstream, which is a key manifestation of viral activity.

By working to manage the virus, this medicine offers supportive therapeutic benefit: it supports the patient during symptomatic episodes and helps improve day-to-day comfort during periods of heightened symptoms.

“This supportive approach contributes to easing the overall symptom load and helps maintain a sense of stability when symptoms are more noticeable.”

---

Quick Fact: Relief for Systemic Imbalance

The medication may assist with easing symptoms linked to organ-specific functional stress and heightened physiological activity, which helps with maintaining functional stability.

Regulatory References

1. NIH MedlinePlus overview

Official Eligibility Map: Who can and cannot use Исентресс (Raltegravir)

Contraindications (Must Not Use)

This medicine is contraindicated (must not be used) in patients with a known hypersensitivity or severe allergic reaction to the active substance, raltegravir, or any of the other ingredients in the formulation.

---

Eligible Populations

• Adults with HIV-1 infection.
• Pediatric patients, including infants, weighing at least 2 kilograms (4.4 pounds). The safety and efficacy for infants weighing less than 2 kg have not been established, and use is generally not recommended in pre-term newborns.

---

Restrictions and Special Considerations

Classification	Population or Condition	Restriction / Status
Formulation Restriction	Patients with Phenylketonuria (PKU)	The chewable tablets contain phenylalanine (aspartame) and are restricted for use in this population.
Physiological State	Breastfeeding	Breastfeeding is not recommended while taking this medicine.
Clinical State	Severe Hepatic Impairment	Use with caution; safety and efficacy have not been established. No dose adjustment is required for mild-to-moderate impairment.
Clinical State	Myopathy/Rhabdomyolysis Risk	Use with caution in patients with a history of or increased risk for these muscle disorders.
Physiological State	Pregnancy	Use is advised only if the potential benefit justifies the potential risk to the fetus. Once-daily 1200 mg dosing is generally not recommended during pregnancy.

This information is strictly based on official regulatory labeling defining which populations are eligible for use, which are contraindicated, and for whom use requires specific cautionary measures.

Interactions with other medicines and products

Official regulatory information describes specific documented interactions for Raltegravir Potassium (Исентресс) based primarily on its metabolic pathway and absorption characteristics. No medicinal products are formally classified as absolutely contraindicated for co-administration in the official labeling.

---

Pharmacokinetic and Absorption Interactions

The primary route of Raltegravir metabolism is UGT1A1-mediated glucuronidation. Interactions are documented with agents that affect this process, leading to altered drug exposure:

• UGT1A1 Inducers: Medicines such as Rifampin may cause a significant decrease in Raltegravir plasma levels, requiring careful consideration due to reduced exposure.
• UGT1A1 Inhibitors: Medicines such as Atazanavir may lead to an increase in Raltegravir plasma levels.

---

Timing and Formulation Constraints

Interactions related to drug absorption require specific administration constraints:

Interacting Product Category	Official Regulatory Statement
Aluminum- and Magnesium-containing Antacids	Co-administration may reduce Raltegravir absorption; separate administration is required.
Food (with Formulation)	Granules for Oral Suspension must be taken with food. Tablets may be taken without regard to food.

No interactions based solely on the CYP450 enzyme system are documented as clinically significant. The official labeling does not include specific warnings for interactions heightened in populations such as those with hepatic or renal impairment.

Raltegravir, an integrase strand transfer inhibitor (INSTI), targets a critical enzymatic step in the viral replication cycle. Its mechanism involves direct and selective binding to the active site of the HIV-1 integrase enzyme. This binding event forms a stable complex with the viral DNA, which sterically and allosterically prevents the integrase from performing its catalytic function within the host cell nucleus.

The primary function of the integrase enzyme is to execute the strand transfer process—the covalent insertion of the viral DNA into the host cell's chromosomal DNA. By interrupting the enzyme’s ability to mediate this transfer, raltegravir blocks the essential integration step. This action results in the formation of aberrant, unintegrated viral DNA that is incapable of producing new viral proteins.

This disruption of the genomic integration cascade prevents the establishment of a productive infection within the host cell, which ultimately limits the ability of the virus to generate functional progeny virions and spread to uninfected immune cells.

How to Use Исентресс (Raltegravir)

The use of Исентресс is governed by established guidelines, defining the precise administration procedures for its role in antiretroviral therapy (ART).

---

Official Administration Guidelines

Entity	Detail
Route of Administration	The medication is designed solely for oral use, defining its administration setting as non-intravenous.
Dosing Schedule	The standard adult regimen is 400 mg twice daily (BID). An alternative regimen of 1200 mg once daily (QD), using two 600 mg film-coated tablets, is also approved for certain patient populations.
Timing in Relation to Meals	Dosing may occur with or without food for all available formulations, providing flexibility in daily scheduling.
Frequency Pattern	Usage follows a fixed once-daily or twice-daily schedule, intended for continuous, long-term administration as part of a combination regimen.
Special Procedural Conditions	The 400 mg and 600 mg film-coated tablets must be swallowed whole and should not be crushed, split, or chewed due to pharmacokinetic considerations. The once-daily regimen requires the use of 600 mg tablets and is not interchangeable with the 400 mg tablets.
Age-Group Administration	Pediatric dosing is determined by weight, typically utilizing the chewable tablets or the granules for oral suspension. No dosage adjustment is generally required for adults with mild to moderate renal or hepatic impairment.
Missed Dose Rule	If a scheduled dose is missed, it should be taken as soon as remembered unless it is nearly time for the next dose; in that scenario, the missed dose should be skipped to maintain the regular schedule.

---

Procedural Structure

The official protocol requires patients to select the appropriate film-coated tablet or alternative form and maintain a fixed once- or twice-daily regimen for long-term use, adhering strictly to the swallowing whole constraint for the standard tablet forms.

Research Evidence / Overview of Studies for Исентресс (Raltegravir)

This section provides a patient-friendly summary of the types of research that have been conducted for Исентресс, describing what was studied and what still requires further investigation, without offering any clinical advice or interpretation of results.

---

Исследование применения у взрослых пациентов, не получавших ранее лечение

Research examining the use of Исентресс in adults starting therapy for the first time has relied heavily on large Randomized Controlled Trials (RCTs). These studies were designed to compare the regimen containing Исентресс against other established standard antiretroviral regimens. The main focus of these trials was to measure the proportion of participants whose HIV-1 RNA (viral load) reached levels below a predefined threshold and to track changes in their CD4+ T-cell counts, which serve as an immune marker.

Studies reported HIV-1 RNA levels observed over the study duration, when administered as part of a combination therapy. The measurements and findings reported apply only to the specific combination therapies that were studied.

---

Исследование применения у пациентов с опытом лечения

For individuals who have previously used other treatments and whose virus has developed resistance, Исентресс was evaluated in placebo-controlled trials as part of a regimen that included other drugs tailored to their resistance profile (Optimized Background Therapy, or OBT). The research was designed to observe the outcomes related to adding Исентресс to a regimen where virologic control was not maintained.

The studies monitored participants over defined time intervals, tracking outcomes such as the proportion of participants achieving viral load suppression and changes in CD4+ T-cell counts. The reported outcomes in this highly experienced population are dependent on the activity of all the drugs included in the OBT.

---

Долгосрочные исследования и длительность наблюдения

Extended monitoring of the outcomes initially recorded has been tracked through follow-up studies, some lasting up to five years (240 weeks). For adults starting therapy for the first time, these extensions were used to monitor the patterns of HIV-1 RNA levels and immune markers over time. Long-term data points often involved fewer participants than the initial short-term trials, reflecting a specific group of patients who continued on the study drug for the entire duration.

---

Неясности и открытые вопросы в исследованиях

While research has established the role of Исентресс across key indications, some aspects of the evidence remain uncertain or limited. Long-term outcomes beyond the 5-year mark are not fully established, as continued monitoring relies primarily on ongoing observational studies. Comparative evidence against some of the very newest antiretroviral agents is often lacking or is derived from indirect comparisons.

Key Studies & References

1. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV
2. Long-term treatment with raltegravir or efavirenz combined with tenofovir/emtricitabine for treatment-naive human immunodeficiency virus-1-infected patients: 156-week results from STARTMRK

Common questions about Исентресс (FAQ)

---

Q: Does Исентресс cure HIV infection?

A: Official product information states that Исентресс is a medication used in combination with other drugs for the treatment of HIV-1 infection. It is not indicated as a cure for HIV. Its therapeutic purpose is to reduce the viral load in the bloodstream as part of continuous management.

Q: Is weight gain a common side effect reported with Исентресс?

A: Weight gain is a reported adverse reaction, but regulatory documents classify it as uncommon or rare. It is not generally listed among the most frequently observed side effects, which tend to be mild symptoms such as headache or nausea. This information is based on controlled clinical trial data.

Q: Are there any known long-term side effects from taking Исентресс for many years?

A: Clinical trials have examined the safety and effectiveness of the medication over extended periods. Studies in adults starting therapy for the first time have collected data on outcomes for up to 240 weeks, which is about 4.6 years. Long-term monitoring beyond this period relies on ongoing surveillance studies and is not as fully established.

Q: Can Исентресс affect the results of my liver or kidney function tests?

A: Official safety information indicates that the medication has been associated with changes in laboratory test results. Specifically, elevations in liver enzymes, such as ALT and AST, and total bilirubin have been reported. This is one reason why routine monitoring of blood tests is typically recommended.

Q: Does Исентресс have a known effect on cholesterol or lipid levels?

A: The official label includes warnings about the possibility of changes to fat and lipid levels in the body. New onset or worsening levels of cholesterol and triglycerides have been reported in patients taking the medication. Routine monitoring is therefore a recommended part of ongoing care.

Q: Is it common for people taking Исентресс to develop a rash?

A: Rash is a documented adverse reaction that may occur. It is important to know that a rash can range in severity from a common, minor skin reaction to a severe, life-threatening hypersensitivity reaction. Concerns regarding the severity or progression of a rash are typically reviewed by a healthcare provider.

Q: Can Исентресс affect my vision?

A: Vision problems have been reported in the context of Immune Reconstitution Inflammatory Syndrome (IRIS). This is a condition that may occur after starting treatment when the recovering immune system begins to fight long-standing infections. It is not listed as a common direct side effect of the drug itself.

Q: Can I consume alcohol in moderation while being treated with Исентресс?

A: Official documents indicate that the medication is not known to interact directly with alcohol (ethanol). However, official guidance usually recommends against excessive or regular consumption of alcohol during treatment.

Q: How long can I safely miss a dose of Исентресс before a risk to resistance develops?

A: Official patient counseling information provides specific guidance on the timing of a missed dose. Regulatory guidance specifies that if a dose is missed by less than 6 hours from the scheduled time, the typical procedure is to take it as soon as possible. If more than 6 hours have passed, regulatory guidance suggests the missed dose is typically skipped to maintain the scheduled regimen.

Q: Can consuming grapefruit juice affect how Исентресс is absorbed?

A: Grapefruit juice is not expected to affect the absorption or concentration of raltegravir. This is because the drug is primarily processed by a different metabolic pathway than the one grapefruit juice is known to influence.

Q: Are there special considerations for using Исентресс in older adults?

A: Regulatory agencies note that information on the use of Исентресс in the elderly population is limited. Consequently, the medication is often used with caution in older adults. Decisions regarding its use typically involve considering the higher frequency of other health issues in this patient group.

Q: What is the evidence about the safety of Исентресс in people with Hepatitis B or C co-infection?

A: Official warnings state that patients who have chronic co-infection with Hepatitis B or C are more likely to experience certain laboratory abnormalities. Specifically, they have a higher risk of developing grade 3 or 4 elevations in liver enzyme levels, requiring careful monitoring.

Q: What kind of routine monitoring is typically required when a person is taking Исентресс?

A: Official patient counseling and warnings recommend periodic laboratory testing while taking this medication. Routine monitoring typically includes checking cholesterol and triglyceride levels, as well as liver function tests, to detect potential changes early.

Q: Can Исентресс cause mood swings or anxiety?

A: Psychiatric adverse reactions have been reported in the safety information for this drug. These reactions include depression, anxiety, and suicidal ideation. This has been noted particularly in individuals with a pre-existing history of such mental health conditions.

Q: Is it true that taking Исентресс can result in fat redistribution (lipodystrophy)?

A: Redistribution or accumulation of body fat, a condition known as lipodystrophy, has been reported in patients receiving antiretroviral therapy. This possibility of change in body fat is noted in official warnings.

Q: Does Исентресс interact with common anti-seizure or anti-convulsant medications?

A: The medication is eliminated primarily through a specific metabolic pathway (UGT1A1). Regulatory documents advise caution when it is co-administered with anti-seizure medications classified as strong inducers, as these could potentially affect the concentration of raltegravir in the body.

Q: How does the chewable tablet form of Исентресс differ from the standard tablet?

A: The chewable tablet and the standard film-coated tablet are not considered bioequivalent. This means they are absorbed differently by the body and achieve different levels in the bloodstream. For this reason, official guidance states that the formulations are not interchangeable.

Q: Is it possible for the HIV virus to become resistant to Исентресс?

A: The official product information confirms that the HIV virus can become resistant to the medication. Virological failure can occur, especially if the drug is not taken exactly as prescribed and in combination with other active agents, as required for combination therapy.

Q: Can I stop taking Исентресс if my viral load becomes undetectable?

A: Official patient counseling information emphasizes the importance of not stopping the medication. Treatment is intended to be continuous for the management of HIV-1 infection. Discontinuation of the drug is typically managed only after consultation with a healthcare provider.

Q: Is there a generic version of Исентресс available?

A: The generic status of the medication depends on the specific tablet strength and region. For example, a generic version for the 400 mg film-coated tablet is not currently available in the US. However, the generic for the 600 mg tablet has been tentatively approved.

Storage and Disposal Conditions for ISENTRESS (Raltegravir)

ISENTRESS must be stored at Controlled Room Temperature, specifically between 68°F to 77°F (20°C to 25°C). The medication must be kept in its original container with the bottle tightly closed and the drying agent (desiccant) remaining inside to ensure protection from moisture. It must not be stored in areas of excess heat or humidity.

Stability and Handling

For the oral suspension granules, the packet must not be opened until immediately before use. Once the suspension is prepared, it must be administered within 30 minutes; any unused portion must be discarded. All formulations must be stored out of the sight and reach of children.

Disposal

Unused or expired ISENTRESS must be disposed of according to local regulations for pharmaceutical waste.